Current ongoing trials evaluating for potential impact of sodium glucose cotransporter 2 inhibitors on RV function, progression of TR, heart failure hospitalization, and cardiovascular endpoints (Reduction-TR [SGLT2 Inhibitor for Severe Tricuspid Regurgitation; NCT05686616], PROVE [Pharmacological Reduction of Right Ventricular Enlargement; NCT04345796], EVENT [Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation; NCT06027307]) may provide more promise to identifying optimal goal-directed medical therapy regimens for the treatment of TR. Here, SLC5A2 is linked to Tricuspid regurgitation.